Analysts' ratings for Mirum Pharmaceuticals (NASDAQ:MIRM) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 2 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 2 | 0 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $55.25, a high estimate of $64.00, and a low estimate of $35.00. This current average represents a 19.93% decrease from the previous average price target of $69.00.
Analyzing Analyst Ratings: A Detailed Breakdown
A comprehensive examination of...
Login or create a forever free account to read this news
Sign up/Log in